SPRB (Spruce Biosciences, Inc.) Stock Market Reviews

crown

search

Read and share opinions on SPRB (Spruce Biosciences, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market

SPRB

Spruce Biosciences, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Nov 10, 2025
What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now?
Oct 15, 2025
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
Oct 6, 2025
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
Sep 15, 2025
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Aug 14, 2025
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
Aug 14, 2025
Spruce Biosciences Announces Reverse Stock Split
Jul 24, 2025
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
Jul 22, 2025
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
Jun 12, 2025
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 6, 2025
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Apr 15, 2025
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Dec 13, 2024
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
Dec 11, 2024

Reviews